137 related articles for article (PubMed ID: 1423010)
41. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction.
Lerman A; Sandok EK; Hildebrand FL; Burnett JC
Circulation; 1992 May; 85(5):1894-8. PubMed ID: 1572045
[TBL] [Abstract][Full Text] [Related]
42. Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation.
Bauersachs J; Hecker M; Busse R
Br J Pharmacol; 1994 Dec; 113(4):1548-53. PubMed ID: 7889312
[TBL] [Abstract][Full Text] [Related]
43. N omega-nitro-L-arginine: a potent inhibitor of endothelium-derived relaxing factor formation.
Ishii K; Chang B; Kerwin JF; Huang ZJ; Murad F
Eur J Pharmacol; 1990 Feb; 176(2):219-23. PubMed ID: 2155799
[TBL] [Abstract][Full Text] [Related]
44. Tumor necrosis factor inhibits stimulated but not basal release of nitric oxide.
Xie J; Wang Y; Lippton H; Cai B; Nelson S; Kolls J; Summer WR; Greenberg SS
Am Rev Respir Dis; 1993 Sep; 148(3):627-36. PubMed ID: 7690209
[TBL] [Abstract][Full Text] [Related]
45. Release of prostacyclin and EDRF from endothelial cells is differentially controlled by extra- and intracellular calcium.
Lückhoff A
Eicosanoids; 1988; 1(1):5-11. PubMed ID: 3152425
[TBL] [Abstract][Full Text] [Related]
46. The mechanisms and significance of the coupled release of endothelium-derived relaxing factor (EDRF) and prostacyclin (PGI2) from endothelial cells.
Hyslop S; de Nucci G
Wien Klin Wochenschr; 1991; 103(14):422-34. PubMed ID: 1926869
[TBL] [Abstract][Full Text] [Related]
47. Endothelium-dependent modulation of responses to endothelin-I in human veins.
Haynes WG; Webb DJ
Clin Sci (Lond); 1993 Apr; 84(4):427-33. PubMed ID: 8482047
[TBL] [Abstract][Full Text] [Related]
48. Nitric oxide but not prostacyclin is an autocrine endothelial mediator.
Schröder H; Strobach H; Schrör K
Biochem Pharmacol; 1992 Feb; 43(3):533-7. PubMed ID: 1371684
[TBL] [Abstract][Full Text] [Related]
49. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.
Hock FJ; Wirth K; Albus U; Linz W; Gerhards HJ; Wiemer G; Henke S; Breipohl G; König W; Knolle J
Br J Pharmacol; 1991 Mar; 102(3):769-73. PubMed ID: 1364851
[TBL] [Abstract][Full Text] [Related]
50. Endothelium-derived relaxing factor (EDRF) from cultured and fresh endothelial cells.
Gryglewski RJ; Trybulec M; Radziszewski W; Swierkosz T; Dudek R; Zembowicz A
Biomed Biochim Acta; 1988; 47(10-11):S61-6. PubMed ID: 2470361
[TBL] [Abstract][Full Text] [Related]
51. Calcium ionophores inhibit the release of endothelin-1 from endothelial cells.
Corder R; Khan N; Anggård EE; Vane JR
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S42-5. PubMed ID: 7509995
[TBL] [Abstract][Full Text] [Related]
52. Quantitative and kinetic characterization of nitric oxide and EDRF released from cultured endothelial cells.
Kelm M; Feelisch M; Spahr R; Piper HM; Noack E; Schrader J
Biochem Biophys Res Commun; 1988 Jul; 154(1):236-44. PubMed ID: 3260776
[TBL] [Abstract][Full Text] [Related]
53. Role of endothelium-derived bradykinin in the control of vascular tone.
Hecker M; Dambacher T; Busse R
J Cardiovasc Pharmacol; 1992; 20 Suppl 9():S55-61. PubMed ID: 1282631
[TBL] [Abstract][Full Text] [Related]
54. Endothelium-derived nitric oxide reduces baseline venous tone in awake instrumented rats.
Glick MR; Gehman JD; Gascho JA
Am J Physiol; 1993 Jul; 265(1 Pt 2):H47-51. PubMed ID: 8102035
[TBL] [Abstract][Full Text] [Related]
55. Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta.
Bult H; Fret HR; Van den Bossche RM; Herman AG
Br J Pharmacol; 1988 Dec; 95(4):1308-14. PubMed ID: 3064856
[TBL] [Abstract][Full Text] [Related]
56. Shear stress-induced release of nitric oxide from endothelial cells grown on beads.
Buga GM; Gold ME; Fukuto JM; Ignarro LJ
Hypertension; 1991 Feb; 17(2):187-93. PubMed ID: 1991651
[TBL] [Abstract][Full Text] [Related]
57. L-arginine, but not N alpha-benzoyl-L-arginine ethyl ester, is a precursor of endothelium-derived relaxing factor.
Fasehun OA; Gross SS; Rubin LE; Jaffe EA; Griffith OW; Levi R
J Pharmacol Exp Ther; 1990 Dec; 255(3):1348-53. PubMed ID: 2175803
[TBL] [Abstract][Full Text] [Related]
58. Release of endothelial mediators and sympathetic transmitters at different coronary flow rates in rabbit hearts.
Wennmalm A; Benthin G; Karwatowska-Prokopczuk E; Lundberg J; Petersson AS
J Physiol; 1991 Apr; 435():163-73. PubMed ID: 1685187
[TBL] [Abstract][Full Text] [Related]
59. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.
Busse R; Fleming I; Hecker M
J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S31-6. PubMed ID: 7508049
[TBL] [Abstract][Full Text] [Related]
60. Nonprostanoid endothelium-derived factors inhibit renin release.
Beierwaltes WH; Carretero OA
Hypertension; 1992 Feb; 19(2 Suppl):II68-73. PubMed ID: 1735597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
